Our unique palladium vibrating mesh technology is a breakthrough in aerosol drug delivery and is at the heart of all our products.
The central aperture plate is just 5 mm in diameter and is perforated with 1000 precision-formed holes, that vibrate at 128,000 times per second, to produce the optimum particle size.
Imagination and innovation are at the heart of what we do, driving us to design and create technology that delivers better patient treatment.
As the world leader in acute care aerosol drug delivery, Aerogen has an extensive Intellectual Property Portfolio of more than 300 granted active and pending patents with coverage in multiple countries across the globe.
These patents are held in various Aerogen/Stamford Devices Ltd. Group companies. In addition Aerogen has co-licensed IP agreements with several institutions and notably Novartis AG and Philips. Aerogen uses IP within this portfolio to protect its market position, as it develops technology designed to enhance the lives of millions of patients in more than 75 countries.1
Certain Aerogen R&D initiatives are co-funded by the European Regional Development Fund and Enterprise Ireland as part of the Border, Midland and Western Regional Operational Programme 2014-2020. This R&D aims to develop novel nebulizer systems aimed at increasing R&D activity which will drive company development.
Research & Development
Aerogen’s dynamic R&D team is dedicated to the continuous improvement and development of aerosol drug delivery technology.
Innovation and creativity are at the core of every product development programme, while Aerogen’s structured five stage gate development process ensures that projects are executed in a methodical and cost effective manner.